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recruited from Melbourne and Brisbane, Australia and randomized to
one of three groups (i) Exercise; (ii) PCST; and (iii) Exercise plus PCST. All
groups visited a physiotherapist for ten sessions over 12 weeks. Par-
ticipants also performed home exercise and/or PCST home practice over
the trial duration. Primary outcomes were overall average pain in the
past week measured using the Visual Analogue Scale (VAS) and self-
reported physical function assessed by the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC). Secondary out-
comes included global rating of change, WOMAC pain, VAS pain on
walking, muscle strength, functional performance, physical activity
levels, health-related quality-of-life and psychological factors. Stat-
istical analyses were performed on an intention-to-treat basis using all
randomized participants.
Results: Two hundred and twenty two participants were randomized
and 184 (82%) completed the 12-month trial. Baseline characteristics
were similar between the groups. For the primary outcomes all groups
showed signiﬁcantly improved VAS pain andWOMAC physical function
following treatment (Fig. 1) with no between-group differences for
pain. However, the integrated program resulted in signiﬁcantly greater
improvements in physical function compared to either intervention
alone at all time points (p < 0.02). Beneﬁts of the integrated program
over both programs alonewere also seen for VASwalking pain, WOMAC
pain, self-efﬁcacy and quality-of-life (p < 0.05). The integrated program
generally showed greater improvements in psychological parameters
compared to exercise alone and greater improvements in functional
performance compared to PCST alone.
Conclusions: Results of this novel study provide evidence of the ben-
eﬁts of an integrated exercise and PCST program for physical function,
pain and a range of physical and psychological outcomes in the short-
and longer-term for people with knee OA. This highlights the potential
for a newmodel of care involving physiotherapists. Advantages of using
physiotherapists to deliver PCST may include better integration with
exercise, increased availability of PCST treatment to those who may not
have access to a psychologist, reduced time and cost for patients, and
reduced overall costs to the health care system.Fig. 1. Mean (SD) change within groups, and adjusted mean [95% CI]
different in the change between groups for primary outcome meas-
ures. The latter were estimated with a mixed effects linear regression
model in which physiotherapists were treated as random effects and the
baseline scores of the outcome variables were entered as a covariate,
together with adjustment for the stratiﬁcation variable of site.332
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Bio-lubrication is a prerequisite for proper joint mobility and is crucial
for prevention of degradative changes of the joint. Phospholipids arecomponents of the synovial ﬂuid and are known to serve as natural
lubricants of cartilage surfaces. MM-II is a novel intra-articular bio-
lubricant made of liposomes suspended in aqueous solution.
Purpose: To test the safety and effectiveness of intra-articular injection
of MM-II in osteoarthritic patients compared with intra-articular hya-
luronic acid (HA) up to 3 months of follow-up in a preliminary double-
blind, randomized clinical study.
Method: Patients with symptomatic unilateral knee OA meeting ACR
criteria, with baseline pain on VAS of more than 40 mm and a stage 2–3
Kellgren Lawrence score on X-ray, were recruited. 40 patients were
randomized into two groups of 20, to receive a single intra-articular
injection of either MM-II or high molecular weight HA (Durolane).
Effectivenessmeasures includedmaximal global pain in the target knee,
recorded by a 100 mm VAS; WOMAC subscales; OMERACT OARSI res-
ponder criteria; PGA, PASS, PAE questions and consumption of para-
cetamol/acetaminophen.
Paracetamol/acetaminophen was the only authorized rescue medi-
cation. Tolerability was assessed by local manifestation deﬁned by an
increase in knee circumference of at least 3 cm in the knee circum-
ference, measured at 2 cm above the upper border of the patella or local
pain increase of more than 30 mm on a 100 mm VAS. Adverse events
were recorded through 90-days of follow-up.
The study was FIM Exploratory non-powered, with descriptive
statistics.
Results: All patients completed the study. In the HA group, the mean
patient age was 66.2 years, 9 males and 11females, and the average BMI
at baseline was 27.4. In the MM-II group, the mean patient age was 63.0
years, 11 males and 9 females, and the average BMI at baseline was 29.3.
The average pain at target knee at baseline was 53.1 mm in the HA
group and 55.9 mm in the MM-II group.
Results relating to WOMAC A pain are summarized in the Fig. 1, and
show a faster response with MM-II, with maximal effect observed on
day 14, which was maintained over time and was associated with a
statistically signiﬁcant difference from baseline pain from day 7. In
the HA group, the onset of pain relief was slower, with an
improvement statistically signiﬁcant change from baseline observed
only on day 90.
Daily acetaminophen intake was lower in the MM-II group, with a
reduction of more than 50 percent in the number of days and total dose
of rescue medication consumption seen following MM-II admin-
istration, compared with HA injection.
The percent of responders to treatment according to the OMERAC-
OARSI response criteria was 52.6, 66.7, 70 & 60 at the day 7, 14, 30 & 90
respectively compared to 30, 36.8, 25, 45 at the HA group.
Local adverse events (inﬂammatory ﬂare) were observed in one patient
at day 3 in the MM-II group and in 4 patient at day 1, 1 patient at day 3,
and 1 patient at day 7 in the HA group.
Patient’s Relative Change in WOMAC A in Target Knee over Time* Statistically signiﬁcant difference from baseline.
Conclusion: Intra-articular injections of MM-II were found to be safe
and effective. The pain-reduction action was more rapid and sustained
up to 3 months compared with HA. Larger randomized controlled trials
are needed to conﬁrm these encouraging results.
